Sigma-Aldrich Corporation Logo

Print Print page   Email Email page   PDF Download PDF    Add to Briefcase Add to Briefcase
« Previous Release | Next Release »

Sigma-Aldrich Reports Q2 2012 Diluted EPS Of $0.94, With Diluted Adjusted EPS Of $0.97. Sales Increase 4% For Q2 2012. Expects Full Year 2012 Adjusted Diluted EPS Of $3.80 To $3.90.


ST. LOUIS, July 24, 2012 /PRNewswire/ --


Q2 2012 Results (all percentages are to comparable periods in 2011)

2012 Outlook (all percentages are compared to full year 2011 results)


Commenting on second quarter 2012 performance, President and CEO Rakesh Sachdev said, "We delivered another solid quarter of sales and EPS growth.  We generated $664 million of sales in second quarter 2012, which represented 3% organic sales growth.  We achieved growth in all geographic regions.  Changes in foreign currency exchange rates since our last earnings call reduced otherwise reportable second quarter 2012 sales and adjusted EPS by $11 million and $0.01, respectively.

"Second quarter 2012 SAFC sales were $223 million, a new quarterly record.  We generated better than expected SAFC organic sales growth of 8%.  We were pleased by the improved performance of our SAFC custom pharma business, which saw solid growth in cGMP manufactured products in second quarter 2012.  Our new Taiwan facility has increased Hitech production capacity for the LED market, and orders continue to ramp-up nicely.  Based on the solid first half of 2012 results and visibility for accelerated sales growth, we are reaffirming our guidance for low double digit organic growth for SAFC sales in the second half of 2012.   

"Second quarter 2012 Research sales were $441 million.  Research sales grew organically 1%, which was at the low end of our expectation.  Asia Pacific and Latin American sales growth remained solid, and organic sales growth from academic customers remained in the low single digits.  Slowdowns in the U.S. and Europe, especially with some of our pharmaceutical customers, reduced organic sales growth in Research from first quarter 2012.  We believe it is prudent to assume that uncertainties in the market will continue for the remainder of 2012.  As a result, we are tempering our second half of 2012 outlook for Research to low single digit organic sales growth as compared with our prior outlook of low-to-mid single digits.  Given this outlook, we are implementing additional cost controls, while remaining fully committed to the long-term growth initiatives that we outlined at our business review in March."

Sachdev concluded, "We expect full year 2012 organic sales growth to be in the low-to-mid single digits as compared to our prior expectation of mid-single digits.  Our updated 2012 adjusted EPS guidance range is $3.80 to $3.90, a $0.10 to $0.15 reduction from prior guidance range of $3.90 to $4.05.  This reduction is driven by more unfavorable changes in foreign currency exchange rates since our prior guidance.  As macroeconomic conditions have impacted Research sales expectations, we have implemented additional cost controls and restructuring efforts.  The cost savings from these activities are expected to offset the negative EPS impact from expected lower Research sales.  We believe that our broad and expanding consumables portfolio in Research, the success of our customer-oriented solutions approach in SAFC, our growth in emerging markets, synergies expected from our recent acquisitions and our continued strong margins and cash flow have enabled us to deliver solid first half of 2012 results and will serve us well in the second half of 2012 and beyond.  Our management team remains fully engaged and committed to delivering a solid second half performance."


Reported second quarter 2012 sales were $664 million and increased 4% over second quarter 2011.  Excluding changes in foreign currency exchange rates, which reduced otherwise reportable sales by 5%, and acquisitions, which increased sales by 6%, second quarter 2012 organic sales growth was 3%.  Second quarter 2012 SAFC sales grew organically by 8% over second quarter 2011, led by strong demand in custom pharma and Hitech.  Hitech sales increased with the opening of a new plant in Taiwan, and sales are expected to accelerate in the second half of 2012.  Second quarter 2012 Research sales grew organically by 1% over second quarter 2011, led by double digit organic growth in Analytical product sales to applied markets.  Biology sales were organically flat, and Chemistry sales declined organically mid-single digits, largely driven by weakness in pharma demand.  A reconciliation of reported to adjusted (organic) sales can be found in the Supplemental Financial Information segment.

The adjusted operating income margin in second quarter 2012 was 25.8% of sales compared to 25.4% of sales in second quarter 2011.   Second quarter 2012 adjusted operating income excludes $4 million, or $0.03 per diluted share, of restructuring costs.  Reported and adjusted operating income includes amortization of acquisition related intangibles of $8 million, or $0.05 earnings per diluted share, in second quarter 2012 compared to $3 million, or $0.02 earnings per diluted share, in second quarter 2011.  A reconciliation of reported to adjusted operating income and margin is provided in the Supplemental Financial Information segment.

The effective tax rate for second quarter 2012 was 31% compared to 29% in second quarter 2011.  The higher effective tax rate for second quarter 2012 when compared to second quarter 2011 is primarily attributable to higher benefits realized in 2011 from favorable tax rates in foreign jurisdictions.  The effective tax rate for full year 2012 is expected to be approximately 30% to 31% of pretax income. 

Free cash flow (defined in the Supplemental Financial Information segment) for the first half of 2012 was $168 million compared to $210 in the first half of 2011.  Free cash flow in 2012 is lower than 2011 due primarily to the timing of vendor payments, as well as greater capital spending related to new facilities.  A reconciliation of net cash provided by operating activities to free cash flow is provided in the Supplemental Financial Information segment.

Other highlights include:



Cash Flow and Debt:  Net cash provided by operating activities for the first half of 2012 was $226 million compared to $254 million for the first half of 2011.  First half of 2012 free cash flow is lower than the same period in 2011 due primarily to the timing of vendor payments made to fund ongoing operations.  Capital expenditures were $58 million in the first half of 2012 compared to $44 million in the first half of 2011.  Free cash flow of $168 million, net debt issuances of $227 million and the partial use of cash on hand for the first half of 2012 were used to return $99 million to shareholders through share repurchases and dividends and fund acquisitions of $389 million.  The Company's debt to capital ratio was 24% at June 30, 2012 and 19% at December 31, 2011. 

Share Repurchases:  In second quarter 2012, the Company repurchased 0.3 million shares at an average share price of $71.10.  There were 121 million shares outstanding at June 30, 2012.  The Company expects to continue to offset the dilutive impact of issuing share based incentive compensation with future repurchases,  the timing and amount of which will depend upon market conditions and other factors.

Board of Directors Declare Quarterly Cash Dividend:

At a Board of Directors meeting held June 26, 2012, the Directors declared a quarterly cash dividend of $0.20 per share.  The dividend is payable on September 14, 2012 to shareholders of record on August 31, 2012.

Cautionary Statement:  This release contains forward-looking statements.  Such statements involve risk and uncertainty, including financial, business environment and projections, and relate to matters that are not historical facts.  Such statements are preceded by, followed by or include the words "believes," "can," "expects," "plans," "anticipates," "should," "enhances," "estimates," "forecasts," "will" or similar expressions.  Additionally, this release contains forward-looking statements relating to future performance, goals, strategic actions and initiatives and similar intentions and beliefs, including, without limitation, statements with respect to the Company's expectations, goals, beliefs, intentions, outlook, plans and the like regarding future sales, earnings, return on equity, cost savings, process improvements, free cash flow, share repurchases, capital expenditures, acquisitions and other matters.  These statements are based on assumptions regarding Company operations, investments, acquisitions and conditions in the markets the Company serves.  The Company believes these statements are reasonable and well founded.  Such statements in this release are subject to risks and uncertainties, including, among others, certain economic, political and technological factors.  Actual results could differ materially from those stated or implied in this release, due to, but not limited to, such factors as (1) global economic conditions, particularly the uncertainties in the Eurozone arising from the sovereign debt crisis and other factors affecting the creditworthiness of our Eurozone customers, (2) changes in pricing and the competitive environment and the global demand for the Company's products, (3) fluctuations in foreign currency exchange rates, (4) changes in research funding and the success of research and development activities, (5) failure of planned sales initiatives in our Research and SAFC business units, (6) dependence on uninterrupted manufacturing operations and global supply chain, (7) changes in the regulatory environment in which the Company operates, (8) changes in worldwide tax rates or tax benefits from domestic and international operations, including the matters described in Note 10 — Income Taxes, to the Company's consolidated financial statements included in Item 8, Part II of the Company's Annual Report on Form 10-K for the year ended December 31, 2011 (the "10-K"), (9) exposure to litigation including product liability claims, (10) the ability to maintain adequate quality standards, (11) reliance on third party package delivery services, (12) an unanticipated increase in interest rates, (13) other changes in the business environment in which the Company operates, (14) the outcome of the outstanding matters described in Note 11 — Contingent Liabilities and Commitments, to the Company's consolidated financial statements included in Item 8, Part II of the 10-K, and (15) acquisitions or divestitures of businesses.  A further discussion of the Company's risk factors can be found in Item 1A of Part I of the 10-K.  The Company does not undertake any obligation to update these forward-looking statements.

About Sigma-Aldrich:  Sigma-Aldrich (Nasdaq: SIAL) is a leading Life Science and High Technology company whose biochemical and organic chemical products, kits and services are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical, diagnostics and high technology manufacturing.  Sigma-Aldrich customers include more than one million scientists and technologists in life science companies, university and government institutions, hospitals and industry.  The Company operates in 38 countries and has approximately 9,100 employees whose objective is to provide excellent service worldwide.  Sigma-Aldrich is committed to accelerating customer success through innovation and leadership in Life Science, High Technology and Service.  For more information about Sigma-Aldrich, please visit its website, at

Non-GAAP Financial Measures:  The Company supplements its disclosures made in accordance with accounting principles generally accepted in the United States (U.S. GAAP) with certain non-GAAP financial measures.  The Company does not, and does not suggest investors should, consider such non-GAAP financial measures in isolation from, or as a substitute for, GAAP financial information.  These non-GAAP measures may not be consistent with the presentation by other companies inside or outside of the Company's industry.  Whenever the Company uses such non-GAAP measures, it provides a reconciliation of such measures to the most closely applicable GAAP measure.  See the Supplemental Financial Information on pages 10 and 11 for these reconciliations.

With over 60% of sales denominated in currencies other than the U.S. dollar, management uses currency adjusted sales growth when analyzing Company performance, and believes it is useful as well to investors to judge the Company's performance.  Organic sales growth data presented in this release excludes currency and acquisitions impacts.  The Company calculates the impact of changes in foreign currency exchange rates by multiplying current period activity by the difference between current period exchange rates and prior period exchange rates.  The result is the defined impact of "changes in foreign currency exchange rates."  While we are able to report past currency impacts, we are unable to estimate changes that may occur later in 2012 to applicable exchange rates.  Any significant changes in currency exchange rates would likely have a significant impact on reported growth rates due to the volume of sales denominated in foreign currencies.

Management also uses the following non-GAAP measures to judge its performance and ability to pursue opportunities that enhance shareholder value:  adjusted net income and EPS; adjusted operating income margin (reconciled on page 11); and free cash flow (defined on page 11).  Due to the uncertain timing of future restructuring and other special charges we are unable to include these charges in the 2012 diluted adjusted EPS forecast or provide reconciliation to the corresponding GAAP measures.  Management believes this non-GAAP information is useful to investors as well.


Consolidated Statements of Income (Unaudited)

(in millions except per share amounts)

Three Months Ended

Six Months Ended

June 30,

June 30,





Net sales

$    664

$    637

$   1,329

$   1,269

Cost of products sold





Gross profit





Selling, general and administrative expenses





Research and development expenses





Restructuring costs





Acquisition transaction costs





Operating income





Interest, net





Income before income taxes





Provision for income taxes





Net income

$    115

$    113

$    232

$    232

Close window | Back to top